<DOC>
	<DOC>NCT01459796</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of rilonacept for patients with gout who are initiating allopurinol.</brief_summary>
	<brief_title>Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>Key Inclusion criteria: Male or female patients aged 18 to 80 years Previously met the preliminary criteria of the ARA for the classification of the acute arthritis of primary gout Serum uric acid greater than or equal to 7.5 mg/dL at the Screening Visit A selfreported history of at least 2 gout flares in the year prior to screening Key Exclusion criteria: Pregnant or nursing, or planning to become pregnant or father a child within 3 months after receiving the last dose of study drug Patients requiring dialysis Patients who have had an organ transplant Persistent chronic or active infections Previous exposure to rilonacept Use of allopurinol, benzbromarone, febuxostat, probenecid or sulfinpyrazone within 84 days prior to the Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>